According to a consensus paper published in The Lancet, polycystic ovary syndrome (PCOS)—a condition affecting an estimated 170 million women worldwide—has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS). The update follows more than 10 years of collaboration involving 22,000 people across six continents, 56 patients, and professional organizations, aiming to correct a historical mislabeling that framed the whole-body hormonal and metabolic disorder as a localized gynaecological issue.
Why the Name Changed from PCOS to PMOS
The original label dates back to a historical accident when early doctors examined ovaries under the microscope and observed clusters of small, fluid-filled sacs they mistook for cysts, according to findings discussed by Dr Elisabet Stener-Victorin. Stener-Victorin serves as the principal investigator of the Reproductive Endocrinology and Metabolism Research Group at the Karolinska Institutet in Sweden. Those structures are actually immature egg follicles stalled in early development, and many diagnosed individuals do not exhibit them at all. The updated three-part name addresses this discrepancy: “polyendocrine” reflects multiple affected hormonal systems, “metabolic” recognizes lifelong health risks, and “ovarian” maintains the necessary link to ovulation problems and infertility.
Did you know?
Diagnosis for the condition took, on average, more than two years under the old label, with many patients told their symptoms were solely fertility or weight issues while receiving little warning about long-term metabolic disease risks.
Health Risks and Clinical Realities of PMOS
PMOS involves a complex matrix of interacting disturbances that begin early in life and last a lifetime, according to researchers at the Karolinska Institutet. Elevated male hormone (androgen) levels, altered brain signalling to the ovaries, and a blunted response to insulin characterize the condition. These disruptions drive higher rates of type 2 diabetes, obesity, fatty liver, cardiovascular disease, depression, anxiety, sleep apnoea, and endometrial cancer. Despite the expanded name, diagnostic criteria remain identical. Patients who already hold a PCOS diagnosis transition directly to PMOS without requiring new medical appointments or diagnostic tests.
Treatment Approaches and Future Patient Care
First-line treatment for PMOS continues to rely on lifestyle modifications, augmented by targeted medications. Clinicians utilize metformin, hormonal contraceptives, and newer pharmaceutical options such as GLP-1 receptor agonists to manage symptoms. While no cure currently exists for the condition, Stener-Victorin notes that establishing the correct terminology provides the foundational framework required to improve patient care outcomes worldwide.
Frequently Asked Questions
Do I need new tests if I was previously diagnosed with PCOS?
No. Diagnostic criteria remain unchanged, and existing diagnoses automatically transfer to PMOS without requiring new hospital appointments or tests.
Why was the word “ovarian” kept in the new name?
Researchers retained “ovarian” because ovulation problems and infertility remain core features of the syndrome.
What are the primary medical treatments for PMOS?
Treatment centers on lifestyle changes combined with medications such as metformin, hormonal contraceptives, and GLP-1 receptor agonists.
Stay Informed on Women’s Health Research
Explore more in-depth coverage of medical breakthroughs and global health policy updates.
Related reading